Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alisertib and Pembrolizumab in Rb-Deficient Head and Neck Squamous Cell Carcinoma
NCT04555837Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Sep 2020
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alisertib in head and neck squamous cell carcinoma (HNSCC), sponsored by University of Texas MD Anderson Cancer Center. Started Sep 2020; status: completed.
02
Drugs
alisertib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT04555837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04555837.